UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
	EXCHANGE ACT OF 1934
	For the quarterly period ended April 3, 2016
	or
	TRANSITION REPORT PURSUANT TO SECTION 13
	OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
¨	For the transition period from __________ to __________

Commission File Number: 001-35797

Zoetis Inc.

(Exact name of registrant as specified in its charter)

Delaware	46-0696167
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)
100 Campus Drive, Florham Park, New Jersey	07932
(Address of principal executive offices)	(Zip Code)

(973) 822-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). ¨ Yes x No

At April 29, 2016, there were 496,202,370 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
PART I — FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
	Condensed Consolidated Statements of Income (Unaudited)	1
	Condensed Consolidated Statements of Comprehensive Income (Unaudited)	2
	Condensed Consolidated (Unaudited) Balance Sheets	3
	Condensed Consolidated Statements of Equity (Unaudited)	4
	Condensed Consolidated Statements of Cash Flows (Unaudited)	5
	Notes to Condensed Consolidated Financial Statements (Unaudited)	6
	Review Report of Independent Registered Public Accounting Firm	22
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	42
Item 4.	Controls and Procedures	42
PART II — OTHER INFORMATION		43
Item 1.	Legal Proceedings	43
Item 1A.	Risk Factors	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	44
Item 5.	Other Information	44
Item 6.	Exhibits	44
SIGNATURES		45

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

	Three Months Ended
	April 3,			March 29,
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2016			2015
Revenue	$	1,162		$	1,102
Costs and expenses:
Cost of sales(a)	389			394
Selling, general and administrative expenses(a)	315			354
Research and development expenses(a)	90			80
Amortization of intangible assets(a)	21			15
Restructuring charges and certain acquisition-related costs	2			1
Interest expense, net of capitalized interest	43			28
Other (income)/deductions—net	(30		)	—
Income before provision for taxes on income	332			230
Provision for taxes on income	128			65
Net income before allocation to noncontrolling interests	204			165
Less: Net income attributable to noncontrolling interests	—			—
Net income attributable to Zoetis Inc.	$	204		$	165
Earnings per share attributable to Zoetis Inc. stockholders:
Basic	$	0.41		$	0.33
Diluted	$	0.41		$	0.33
Weighted-average common shares outstanding:
Basic	497.4			501.1
Diluted	499.5			503.2
Dividends declared per common share	$	0.095		$	0.083

^(a)  Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate, in the condensed consolidated statements of income.

See notes to condensed consolidated financial statements.

1 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

	Three Months Ended
	April 3,			March 29,
(MILLIONS OF DOLLARS)	2016			2015
Net income before allocation to noncontrolling interests	$	204		$	165
Other comprehensive income/(loss), net of taxes and reclassification adjustments:
Foreign currency translation adjustments, net	2			(118		)
Benefit plans: Actuarial gains, net(a)	1			1
Total other comprehensive income/(loss), net of tax	3			(117		)
Comprehensive income before allocation to noncontrolling interests	207			48
Less: Comprehensive (loss)/income attributable to noncontrolling interests	(1		)	1
Comprehensive income attributable to Zoetis Inc.	$	208		$	47

^(a)  Presented net of reclassification adjustments and tax impacts, which are not significant in any period presented. Reclassification adjustments related to benefit plans are generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, general and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income.

See notes to condensed consolidated financial statements.

2 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	April 3,			December 31,
	2016			2015
(MILLIONS OF DOLLARS, EXCEPT SHARE AND PER SHARE DATA)	(Unaudited)
Assets
Cash and cash equivalents	$	675		$	1,154
Accounts receivable, less allowance for doubtful accounts of $32 in 2016 and $34 in 2015	908			937
Inventories	1,461			1,467
Assets held for sale	27			71
Other current assets	236			201
Total current assets	3,307			3,830
Property, plant and equipment, less accumulated depreciation of $1,248 in 2016 and $1,208 in 2015	1,317			1,307
Goodwill	1,459			1,455
Identifiable intangible assets, less accumulated amortization	1,210			1,190
Noncurrent deferred tax assets	112			82
Other noncurrent assets	48			49
Total assets	$	7,453		$	7,913
Liabilities and Equity
Short-term borrowings	$	4		$	5
Current portion of long-term debt	—			400
Accounts payable	210			293
Dividends payable	49			47
Accrued expenses	552			676
Accrued compensation and related items	166			234
Income taxes payable	118			63
Liabilities associated with assets held for sale	4			4
Other current liabilities	60			59
Total current liabilities	1,163			1,781
Long-term debt, net of discount and issuance costs	4,464			4,463
Noncurrent deferred tax liabilities	270			264
Other taxes payable	123			63
Other noncurrent liabilities	246			251
Total liabilities	6,266			6,822
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value: 1,000,000,000 authorized, none issued	—			—
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,835 and 501,808,229 shares issued; 496,416,809 and 497,400,113 shares outstanding at April 3, 2016, and December 31, 2015, respectively	5			5
Treasury stock, at cost, 5,475,026 and 4,408,116 shares of common stock at April 3, 2016, and December 31, 2015, respectively	(245		)	(203		)
Additional paid-in capital	1,007			1,012
Retained earnings	1,016			876
Accumulated other comprehensive loss	(618		)	(622		)
Total Zoetis Inc. equity	1,165			1,068
Equity attributable to noncontrolling interests	22			23
Total equity	1,187			1,091
Total liabilities and equity	$	7,453		$	7,913

See notes to condensed consolidated financial statements.

3 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

	Zoetis
													Accumulated			Equity
							Additional						Other			Attributable to
		Common		Treasury			Paid-in			Retained			Comprehensive			Noncontrolling			Total
(MILLIONS OF DOLLARS)		Stock(a)		Stock(a)			Capital			Earnings			Loss			Interests			Equity
Balance, December 31, 2014		$	5	$	—		$	958		$	709		$	(361	)	$	26		$	1,337
Three months ended March 29, 2015
Net income		—		—			—			165			—			—			165
Other comprehensive income/(loss)		—		—			—			—			(118		)	1			(117		)
Share-based compensation awards(b)		—		(2		)	10			—			—			—			8
Treasury stock acquired(c)		—		(47		)	—			—			—			—			(47		)
Employee benefit plan contribution from Pfizer Inc.(d)		—		—			1			—			—			—			1
Dividends declared		—		—			—			(42		)	—			—			(42		)
Balance, March 29, 2015		$	5	$	(49	)	$	969		$	832		$	(479	)	$	27		$	1,305
Balance, December 31, 2015		$	5	$	(203	)	$	1,012		$	876		$	(622	)	$	23		$	1,091
Three months ended April 3, 2016
Net income		—		—			—			204			—			—			204
Other comprehensive income/(loss)		—		—			—			—			4			(1		)	3
Share-based compensation awards (b)		—		34			(6		)	(15		)	—			—			13
Treasury stock acquired(c)		—		(76		)	—			—			—			—			(76		)
Employee benefit plan contribution from Pfizer Inc.(d)		—		—			1			—			—			—			1
Dividends declared		—		—			—			(49		)	—			—			(49		)
Balance, April 3, 2016		$	5	$	(245	)	$	1,007		$	1,016		$	(618	)	$	22		$	1,187

^(a)  As of April 3, 2016, and March 29, 2015, there were 496,416,809 and 500,367,604 outstanding shares of common stock, respectively, and 5,475,026 and 1,087,313 shares of treasury stock, respectively. Treasury stock is recognized at the cost to reacquire the shares. For additional information, see Note 13. Stockholders' Equity.

^(b)  Includes the issuance of shares of Zoetis Inc. common stock and the reissuance of treasury stock in connection with the vesting of employee share-based awards. Upon reissuance of treasury stock, differences between the proceeds from reissuance and the cost of the treasury stock that result in gains are recorded in Additional paid-in capital. Losses are recorded in Additional paid-in capital to the extent that they can offset previous gains. If no such credit exits, the differences are recorded in Retained earnings. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-Based Payments and Note. 13. Stockholders' Equity.

^(c)  Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see Note 13. Stockholders' Equity.

^(d)  Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 11. Benefit Plans.

See notes to condensed consolidated financial statements.

4 |

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three Months Ended
	April 3,			March 29,
(MILLIONS OF DOLLARS)	2016			2015
Operating Activities
Net income before allocation to noncontrolling interests	$	204		$	165
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization expense	57			48
Share-based compensation expense	9			10
Restructuring, net of payments	2			—
Asset write-offs and asset impairments	—			1
Gains on sales of assets	(33		)	—
Provision for losses on inventory	16			18
Deferred taxes	(25		)	(3		)
Employee benefit plan contribution from Pfizer Inc.	1			1
Other non-cash adjustments	1			3
Other changes in assets and liabilities, net of acquisitions and divestitures
Accounts receivable	21			(4		)
Inventories	(3		)	(77		)
Other assets	(36		)	(5		)
Accounts payable	(84		)	(26		)
Other liabilities	(193		)	(82		)
Other tax accounts, net	114			11
Net cash provided by operating activities	51			60
Investing Activities
Purchases of property, plant and equipment	(45		)	(45		)
Acquisitions	(12		)	(230		)
Net proceeds from sales of assets	75			1
Net cash provided by (used in) investing activities	18			(274		)
Financing Activities
Decrease in short-term borrowings, net	(1		)	(5		)
Principal payments on long-term debt	(400		)	—
Payment of contingent consideration related to previously acquired assets	(22		)	—
Share-based compensation-related proceeds, net of taxes paid on withholding shares and excess tax benefits(a)	3			1
Purchases of treasury stock(b)	(76		)	(48		)
Cash dividends paid	(47		)	(42		)
Net cash used in financing activities	(543		)	(94		)
Effect of exchange-rate changes on cash and cash equivalents	(5		)	(15		)
Net decrease in cash and cash equivalents	(479		)	(323		)
Cash and cash equivalents at beginning of period	1,154			882
Cash and cash equivalents at end of period	$	675		$	559
Supplemental cash flow information
Cash paid during the period for:
Income taxes	$	49		$	52
Interest, net of capitalized interest	58			58
Non-cash transactions:
Purchases of property, plant and equipment	9			10
Contingent purchase price consideration	27			22
Dividends declared, not paid	49			42

^(a)  Effective 2016, excess tax benefits are reflected within operating activities. See Note 3. Significant Accounting Policies for additional information.

^(b)  Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see Note 13. Stockholders' Equity.

See notes to condensed consolidated financial statements.

5 |

ZOETIS INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Organization

Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. We organize and operate our business in two geographic regions: the United States (U.S.) and International.

We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the United States are as of and for the three-month periods ended February 28, 2016, and February 22, 2015.

We follow a 13-week quarterly accounting cycle pursuant to which the first three quarters end on a Sunday and the fiscal year always ends on December 31 for our operations in the United States and on November 30 for subsidiaries operating outside the United States. As a result of this convention, the first quarter of fiscal 2016 had six additional days and the fourth quarter of fiscal 2016 will have five less days compared with the respective quarters of fiscal 2015. The first quarter of fiscal 2016 ended on April 3, 2016, while the first quarter of fiscal 2015 ended on March 29, 2015, except as noted above for subsidiaries operating outside the United States.

Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2015 Annual Report on Form 10-K.

Certain reclassifications have been made to prior year data to conform to current year presentation.

3. Significant Accounting Policies

New Accounting Standards

In March 2016, the Financial Accounting Standards Board (FASB) issued an accounting standards update which simplifies the accounting for employee share-based payments. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement, and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. The standard also clarifies that all cash payments made to taxing authorities on the employees' behalf for shares withheld should be presented as financing activities on the statements of cash flows and provides for a policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. The provisions of the new standard are effective beginning January 1, 2017 and early adoption is permitted if all amendments are adopted in the same period. We have elected to early adopt the new standard effective January 1, 2016. Excess tax benefits of $4 million generated during the first quarter of 2016 are reflected as a component of Provision for taxes on income as presented in the condensed consolidated statements of income. We have elected to apply the change in cash flow classification for excess tax benefits on a prospective basis. Cash payments made to taxing authorities on the behalf of company employees are reflected as a financing outflow in the condensed consolidated statements of cash flows, consistent with prior years. We will continue to include the impact of estimated forfeitures when determining share-based compensation expense.

In February 2015, the FASB issued an accounting standards update that provides revised guidance on whether to consolidate certain legal entities, such as limited partnerships, limited liability corporations and securitization structures. We adopted this guidance effective January 1, 2016. This guidance did not have a significant impact on our consolidated financial statements.

In February 2016, the FASB issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right of use asset. Leases will be classified as financing or operating which will drive the expense recognition pattern. For lessees, the income statement presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively. Accounting for lessors remains largely unchanged. Companies may elect to exclude short-term leases. The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of

6 |

cash flows arising from leases. The provisions of the new standard are effective beginning January 1, 2019, for annual and interim reporting periods. Early adoption is permitted beginning on January 1, 2017. The new standard requires a modified retrospective adoption approach, at the beginning of the earliest comparative period presented in the financial statements. We continue to assess the potential impact that adopting this new guidance will have on our consolidated financial statements.

In July 2015, the FASB issued an accounting standards update to simplify the measurement of inventory by requiring that inventory be measured at the lower of cost or net realizable value, rather than at the lower of cost or market, with market being defined as either replacement cost, net realizable value or net realizable value less a normal profit margin. The provisions of the new standard are effective beginning January 1, 2017, for annual and interim reporting periods. The guidance will be adopted prospectively and early adoption is permitted. We plan to adopt this guidance as of January 1, 2017, the required effective date, and do not expect this guidance to have a significant impact on our consolidated financial statements.

In May 2014, the FASB issued an accounting standards update that outlines a new, single comprehensive model for companies to use in accounting for revenue arising from contracts with customers. This update supersedes most current revenue recognition guidance under U.S. GAAP. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance includes a five-step model for determining how, when and how much revenue should be recognized. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of the new standard are effective beginning January 1, 2018, for annual and interim reporting periods. Early adoption is permitted beginning on January 1, 2017. The new standard allows for either full retrospective or modified retrospective transition upon adoption. We continue to assess the transition method we will elect for adoption as well as the potential impact that adopting this new guidance will have on our consolidated financial statements.

4. Acquisitions and Divestitures

A. Acquisitions

Acquisition of Pharmaq

On November 9, 2015, we completed the acquisition of Pharmaq, a privately held Norwegian aquaculture company. We acquired 100% of the issued share capital of Pharmaq for an aggregate cash purchase price of $765 million, adjusted to reflect cash, working capital and net indebtedness as of the closing date for net cash consideration transferred to the seller of $668 million. The acquisition expands the Zoetis aquaculture portfolio.

The transaction was accounted for as a business combination, with the assets acquired and liabilities assumed measured at their respective acquisition date fair values as summarized below:

(MILLIONS OF DOLLARS)
Cash and cash equivalents	$	16
Accounts receivable(a)	21
Inventories(b)	42
Other current assets	2
Property, plant and equipment	11
Intangible assets(c)	550
Accounts payable	(4		)
Accrued expenses(d)	(38		)
Accrued compensation and related items	(4		)
Long-term debt(d)	(89		)
Noncurrent deferred tax liabilities(e)	(139		)
Other non-current liabilities	(2		)
Total net assets acquired	366
Goodwill(f)	302
Total consideration	$	668

^(a)  Accounts receivable were measured at fair value as of the acquisition date and are substantially comprised of gross trade receivables of $21 million, $1 million of which is expected to be uncollectible.

^(b)  Inventories recorded as of the acquisition date reflect fair value adjustments of $17 million which relates primarily to finished goods. The fair value was calculated based on estimated selling profit margin.

^(c)  The acquisition date fair value of intangible assets acquired was determined using the income approach and consists of the following: $160 million related to currently marketed vaccine products, $30 million related to currently marketed therapeutics, $80 million related to customer relationships and $280 million related to in-process research and development (IPR&D). The most significant IPR&D project acquired, with an acquisition date fair value of $150 million, relates to the salmon rickettsial syndrome (SRS) vaccine. The vaccine was commercially launched, subsequent to the acquisition, during November 2015. Other significant acquired IPR&D projects relate to a vaccine for pancreatic disease, “PD” and Alphaflux, a therapeutic drug for the treatment of sea lice and vaccine technology for new species including Tilapia and Pangasius, were assigned acquisition date fair values of $50 million, $40 million, and $40 million,

7 |

respectively. Vaccine developed technology and customer relationships will be amortized over a 15 year useful life while therapeutic developed technology will be amortized over 10 years.

^(d)  Pharmaq callable bonds and derivative contracts were recorded at acquisition date fair value and settled immediately following the closing.

^(e)  The Pharmaq acquisition was structured as a stock purchase therefore we assumed the historical tax bases of its assets and liabilities. We also established net tax assets and liabilities associated with the fair value adjustments recorded as part of the opening balance sheet. The components of the Pharmaq net deferred tax liability are included within amounts reported in Note 7. Income Taxes.

^(f)  Goodwill of $302 million is the excess of consideration transferred over the value of net assets acquired and was allocated to our existing reportable segments and is primarily attributable to corporate synergies related to platform functions. The primary strategic purpose of the acquisition was to enhance the company’s existing product portfolio by enabling Zoetis to further expand into aquaculture. The goodwill recorded is not deductible for tax purposes.

All amounts recorded are subject to final valuation; however, any difference between such amounts and the final fair value determination for net assets acquired is not expected to be material to our consolidated financial statements. Any adjustments to our preliminary purchase price allocation identified during the measurement period, which will not exceed one year from the acquisition date, will be accounted for prospectively.

Acquisition of Abbott Animal Health

On February 10, 2015, we completed the purchase of certain assets of Abbott Animal Health (AAH), a subsidiary of Abbott Laboratories (Abbott). AAH is a companion animal health business focused on the veterinary surgical suite. The purchase expands our companion animal product portfolio to include veterinarian solutions for anesthesia, pain management, and the diabetes monitoring.

The $254 million purchase price included net cash of $229 million and an additional contingent payment of $25 million (acquisition date fair value of $22 million) which was due to Abbott within one year of the acquisition date, subject to certain deductions in the event of sales disruptions due to supply issues. The $25 million payment was made to Abbott in February 2016.

The transaction was accounted for as a business combination, with the net assets acquired measured at their respective acquisition date fair values. Final amounts recorded for the acquisition include $12 million of inventory, $8 million of IPR&D associated with oncology and osteoarthritis projects, $5 million of trade names related to diabetes and pain management products, $16 million of developed technology assets associated with pain management and surgical products, $23 million of other intangible assets including a favorable supply agreement and product exclusivity rights and property, plant and equipment of less than $1 million. Trade names and developed technology assets will be amortized over 15 years while other intangible assets acquired have a weighted average useful life of 5 years.

Goodwill of $187 million is the excess of consideration transferred over the fair value of assets acquired and was allocated to our reportable segments and is predominantly attributable to synergies expected to be realized through the integration of AAH operations into the existing Zoetis business. The goodwill recorded is deductible for tax purposes.

The valuation was finalized during the first quarter of 2016. Final amounts noted above reflect a net increase of $14 million in intangible assets from the preliminary valuation, offset by a decrease in goodwill and inventory fair value adjustments.

Acquisition-related costs of the transaction were expensed as incurred and are not material to our consolidated statements of income.

B. Divestitures

On January 14, 2016, we entered into ashare purchase agreement with Yung Shin Pharmaceutical Industrial Co., Ltd., a pharmaceutical company with an animal health business and headquarters in Taiwan, to divest our 55 percent ownership share of our Taiwan joint venture including our manufacturing site in Hsinchu, Taiwan. The agreement also includes the divestment of a portfolio of products in conjunction with our comprehensive operational efficiency program. These products include medicated feed additives, anti-infective medicines and nutritional premixes for livestock, sold primarily in Taiwan and in international markets. Under the agreement, Zoetis will receive approximately $13 million in cash. We expect to complete the transaction in the second quarter of 2016, pending the successful completion of customary regulatory review in Taiwan. The assets and liabilities of the joint venture were included within held for sale classification as of April 3, 2016, as described below.

On February 12, 2016, we completed the sale of two of our manufacturing sites in the United States: Laurinburg, North Carolina, and Longmont, Colorado, to Huvepharma NV (Huvepharma), a European animal health company. Huvepharma also assumed the assets and operations and the lease of our manufacturing and distribution site in Van Buren, Arkansas. The agreement included the sale of a portfolio of products in conjunction with our comprehensive operational efficiency program. These products included medicated feed additives, water soluble therapeutics and nutritionals for livestock sold in the U.S. and international markets. The related assets had been previously included within held for sale classification as of December 31, 2015.

On February 17, 2016, we completed the sale of our manufacturing site in Haridwar, India to the India-based pharmaceutical company Zydus Cadila (Cadila Healthcare Ltd.). The agreement also included the sale of a portfolio of our products in conjunction with our comprehensive operational efficiency program. These products included medicated feed additives, anti-infectives, parasiticides, and nutritionals for livestock, sold primarily in India. These assets had been previously included within held for sale classification as of December 31, 2015.

In the first quarter of 2016, we received total cash proceeds of $75 million related to the divestitures of our India and U.S. manufacturing sites noted above. We recognized a net pre-tax gain of approximately $33 million related to these transactions. The gain was recorded within Other (income)/deductions— net.

The divestiture transactions required transitional supply and service agreements, including technology transfers, where necessary and appropriate, as well as other customary ancillary agreements.

8 |

Assets Held for Sale

During the fourth quarter of 2015, we met the criteria for held for sale classification for our Taiwan joint venture, inclusive of its related manufacturing site as discussed above. As of April 3, 2016, we recorded assets and liabilities held for sale of $27 million and $4 million, respectively. Assets held for sale comprise accounts receivable ($4 million), inventory ($3 million), property, plant and equipment ($15 million), intangible assets ($2 million), other assets ($2 million), and goodwill ($1 million). Liabilities held for sale comprise accounts payable ($1 million) and other liabilities ($3 million). We expect to finalize the sale of this joint venture, inclusive of its related manufacturing site, within one year.

5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. In connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as functions such as business technology, shared services and corporate operations.

During 2015, we launched a comprehensive operational efficiency program, which was incremental to the previously announced supply network strategy. These initiatives have focused on reducing complexity in our product portfolios through the elimination of approximately 5,000 product stock keeping units (SKUs), changing our selling approach in certain markets, reducing our presence in certain countries, and planning to sell or exit ten manufacturing sites over the long term. As of April 3, 2016, we divested three U.S. manufacturing sites, one international manufacturing site, and entered into an agreement to divest our 55 percent ownership share of our Taiwan joint venture, inclusive of its related manufacturing site. See Note 4B. Acquisitions and Divestitures: Divestitures for additional information. We are also continuing to optimize our resource allocation and efficiency by reducing resources associated with non-customer facing activities and operating more efficiently as a result of less internal complexity and more standardization of processes. As part of these initiatives, we expect to reduce certain positions through divestitures, normal attrition and involuntary terminations by approximately 2,000 to 2,500, subject to consultations with works councils and unions in certain countries. As of April 3, 2016, approximately 1,400 positions had been eliminated and additional reductions are expected primarily over the next six to nine months.

As a result of our operational efficiency initiative, we recorded restructuring charges of $2 million related to employee termination costs ($1 million) and exit costs ($1 million) during the three months ended April 3, 2016.

The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives are as follows:

	Three Months Ended
	April 3,			March 29,
(MILLIONS OF DOLLARS)	2016			2015
Restructuring charges and certain acquisition-related costs:
Integration costs(a)	$	—		$	1
Restructuring charges(b):
Employee termination costs	1			—
Exit costs	1			—
Total Restructuring charges and certain acquisition-related costs	2			1
Other costs associated with cost-reduction/productivity initiatives:
Other operational efficiency initiative charges
Selling, general and administrative expenses:
Consulting fees	3			10
Other (income)/deductions:
Net gain on sale of assets(c)	(33		)	—
Total other operational efficiency initiative charges	(30		)	10
Other supply network strategy charges
Cost of sales:
Accelerated depreciation	1			—
Consulting fees	2			5
Total other supply network strategy charges	3			5
Total costs associated with acquisitions and cost-reduction/productivity initiatives	$	(25	)	$	16

9 |

^(a)  Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

^(b)  The restructuring charges for the three months endedApril 3, 2016, relate to our operational efficiency initiative.

The restructuring charges for the three months endedApril 3, 2016, are associated with the following: U.S. ($1 million benefit), International ($1 million benefit) and Manufacturing/research/corporate ($4 million).

^(c)  For the three months endedApril 3, 2016, represents the gain on sale of certain manufacturing sites and products as part of our operational efficiency initiative.

The components of, and changes in, our restructuring accruals are as follows:

	Employee
	Termination			Exit
(MILLIONS OF DOLLARS)	Costs			Costs			Accrual
Balance, December 31, 2015(a)	$	221		$	1		$	222
Provision	1			1			2
Utilization and other(b)	(37		)	(1		)	(38		)
Balance, April 3, 2016(a)	$	185		$	1		$	186

^(a)  At April 3, 2016, and December 31, 2015, included in Accrued expenses ($136 million and $162 million, respectively) and Other noncurrent liabilities ($50 million and $60 million, respectively).

^(b)  Includes adjustments for foreign currency translation.

10 |

6. Other (Income)/Deductions—Net

The components of Other (income)/deductions—net are as follows:

	Three Months Ended
	April 3,			March 29,
(MILLIONS OF DOLLARS)	2016			2015
Royalty-related income	$	(7	)	$	(7	)
Net gain on sale of assets(a)	(33		)	—
Foreign currency loss(b)	9			8
Other, net	1			(1		)
Other (income)/deductions—net	$	(30	)	$	—

^(a)  For the three months ended April 3, 2016, represents the net gain on sale of certain manufacturing sites and products as part of the operational efficiency initiative.

^(b)  Primarily driven by costs related to hedging and exposures to certain emerging market currencies.

7. Income Taxes

A. Taxes on Income

The effective tax rate was 38.6% for the three months ended April 3, 2016, compared with 28.3% for the three months ended March 29, 2015. The higher effective tax rate for the three months ended April 3, 2016, was primarily attributable to:

• changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings (i) from operations and (ii) from restructuring charges related to the operational efficiency initiative and supply network strategy, as well as repatriation costs. The jurisdictional mix of earnings can vary as a result of repatriation decisions and operating fluctuations in the normal course of business, the impact of non-deductible items and the extent and location of other income and expense items, such as restructuring charges/(benefits), asset impairments and gains and losses on asset divestitures; and

• a $35 million net discrete tax expense related to changes in uncertain tax positions due to the impact of the European Commission’s negative decision on the excess profits rulings in Belgium (see C. Tax Contingencies), partially offset by a revaluation of the company's deferred tax assets and liabilities using the Belgium tax rates expected to be in place going forward as a result of the decision,

partially offset by:

• a $10 million and $9 million discrete tax benefit recorded in the first quarter of 2016 and 2015, respectively, related to a revaluation of deferred taxes as a result of a change in statutory tax rates; and

• a $4 million discrete tax benefit recorded in the first quarter of 2016 related to the adoption of a new accounting standard requiring the excess tax benefits for share-based payments to be recognized as a component of Provision for taxes on income. See Note 3. Significant Accounting Policies.

B. Deferred Taxes

As of April 3, 2016, the total net deferred income tax liability of $158 million is included in Noncurrent deferred tax assets ($112 million) and Noncurrent deferred tax liabilities ($270 million).

As of December 31, 2015, the total net deferred income tax liability of $182 million is included in Noncurrent deferred tax assets ($82 million) and Noncurrent deferred tax liabilities ($264 million).

C. Tax Contingencies

As of April 3, 2016, the tax liabilities associated with uncertain tax positions of $120 million (exclusive of interest and penalties related to uncertain tax positions of $8 million) are included in Noncurrent deferred tax assets ($5 million) and Other taxes payable ($115 million).

As of December 31, 2015, the tax liabilities associated with uncertain tax positions of $61 million (exclusive of interest and penalties related to uncertain tax positions of $7 million) are included in Noncurrent deferred tax assets ($6 million) and Other taxes payable ($55 million).

The increase in tax liabilities associated with uncertain tax positions as of April 3, 2016, is primarily due to a tax charge of approximately $59 million related to the impact of the European Commission’s negative decision on January 11, 2016, regarding the excess profits rulings in Belgium. This charge, related to the recovery of prior tax benefits for the periods 2013 through 2015, does not include any benefits associated with a successful appeal of the decision, nor does it reflect guidance we expect to receive from the Belgian government on the methodology and timing of the recovery of prior tax benefits. 

Aside from the above, our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could

11 |

materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

8. Financial Instruments

A. Debt

Credit Facilities

In December 2012, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which became effective in February 2013 upon the completion of the initial public offering and expires in December 2017. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.25:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. On November 10, 2015, we designated the acquisition of Pharmaq a material acquisition under the revolving credit agreement. For additional information, see Note 4. Acquisitions and Divestitures. On February 19, 2016, we amended this financial covenant to add back to Adjusted Consolidated EBITDA, any operational efficiency restructuring charge (defined as charges recorded by the company during the second quarter of 2015, related to our operational efficiency program announced on May 5, 2015, in an aggregate amount for all such charges not to exceed $237 million) and Venezuela-related charges (defined as the write-down, impairment and other charges recorded by the company during the fourth quarter of 2015 relating to Venezuela, in an aggregate amount for all such charges not to exceed $95 million).

The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants.

We were in compliance with all financial covenants as of April 3, 2016, and December 31, 2015. There were no amounts drawn under the credit facility as of April 3, 2016, or December 31, 2015.

We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of April 3, 2016, we had access to $91 million of lines of credit which expire at various times through 2017. Short-term borrowings outstanding related to these facilities were $4 million as of both April 3, 2016, and December 31, 2015.

Commercial Paper Program

In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of April 3, 2016, and December 31, 2015, there was no commercial paper issued under this program.

Short-Term Borrowings

As of April 3, 2016, short-term borrowings outstanding, including lines of credit, were $4 million, with a weighted-average interest rate of 5.4%. As of December 31, 2015, short-term borrowings outstanding, including lines of credit, were $5 million, with a weighted-average interest rate of 5.2%.

Senior Notes and Other Long-Term Debt

On November 13, 2015, we issued $1.25 billion aggregate principal amount of our senior notes (2015 senior notes), with an original issue discount of $2 million. On January 28, 2013, we issued $3.65 billion aggregate principal amount of our senior notes (the 2013 senior notes offering) in a private placement, with an original issue discount of $10 million.

There was no current portion of long-term debt as of April 3, 2016. The current portion of long-term debt was $400 million as of December 31, 2015, with a weighted-average interest rate of 1.150%.

The 2013 and 2015 senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our, and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the 2013 and 2015 senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the 2013 and 2015 senior notes, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2013 senior notes due 2023 pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the 2013 and 2015 senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding 2013 and 2015 senior notes at a price equal to 101% of the aggregate principal amount of the 2013 and 2015 senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

12 |

The components of our long-term debt are as follows:

	April 3,			December 31,
(MILLIONS OF DOLLARS)	2016			2015
1.150% 2013 senior notes due 2016	$	—		$	400
1.875% 2013 senior notes due 2018	750			750
3.450% 2015 senior notes due 2020	500			500
3.250% 2013 senior notes due 2023	1,350			1,350
4.500% 2015 senior notes due 2025	750			750
4.700% 2013 senior notes due 2043	1,150			1,150
	4,500			4,900
Unamortized debt discount / debt issuance costs	(36		)	(37		)
Less current portion of long-term debt	—			(400		)
Long-term debt	$	4,464		$	4,463

The fair value of our long-term debt, including the current portion of long-term debt, was $4,533 million and $4,759 million as of April 3, 2016, and December 31, 2015, respectively, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from, or corroborated by, observable market data and Zoetis’ credit rating (Level 2 inputs).

The principal amount of long-term debt outstanding, as of April 3, 2016, matures in the following years:

											After
(MILLIONS OF DOLLARS)	2017		2018		2019		2020		2021		2021		Total
Maturities	$	—	$	750	$	—	$	500	$	—	$	3,250	$	4,500

Interest Expense

Interest expense, net of capitalized interest, was $43 million and $28 million for the three months endedApril 3, 2016, and March 29, 2015, respectively. Capitalized interest was $1 million for each of the three months endedApril 3, 2016, and March 29, 2015.

B. Derivative Financial Instruments

Foreign Exchange Risk

A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of derivative financial instruments. These financial instruments serve to protect net income against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. The aggregate notional amount of foreign exchange derivative financial instruments offsetting foreign currency exposures was $1.1 billion and $1.4 billion, as of April 3, 2016, and December 31, 2015, respectively. The derivative financial instruments primarily offset exposures in the Australian dollar, Canadian dollar, Chinese Yuan, euro, Japanese Yen, and U.K. pound. The vast majority of the foreign exchange derivative financial instruments mature within 60 days and all mature within 180 days.

All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the condensed consolidated balance sheet. The company has not designated the foreign currency forward-exchange contracts as hedging instruments. We recognize the gains and losses on forward-exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.

Interest Rate Risk

The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing. In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. To the extent these hedges of cash flows related to anticipated debt are effective, any unrealized gains or losses on the forward-starting interest rate swaps are reported in Accumulated other comprehensive loss and are recognized in income over the life of the future fixed-rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.

In the first quarter of 2016, we entered into an interest rate swap with an aggregate notional value of $50 million, having a term of ten years and an effective date and mandatory termination date of December 2017. We designated this swap as a cash flow hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 1.875% 2013 senior note due in 2018. The fair value in Other current liabilities and the losses, net of tax, in Accumulated other comprehensive loss, were insignificant.

13 |

Fair Value of Derivative Instruments

The classification and fair values of derivative instruments are as follows:

		Fair Value of Derivatives
		April 3,			December 31,
(MILLIONS OF DOLLARS)	Balance Sheet Location	2016			2015
Derivatives Not Designated as Hedging Instruments
Foreign currency forward-exchange contracts	Other current assets	$	7		$	8
Foreign currency forward-exchange contracts	Other current liabilities	(12		)	(10		)
Total derivatives not designated as hedging instruments		$	(5	)	$	(2	)

We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.

The amounts of gains on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions, are as follows:

	Three Months Ended
	April 3,		March 29,
(MILLIONS OF DOLLARS)	2016		2015
Foreign currency forward-exchange contracts	$	1	$	7

These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.

9. Inventories

The components of inventory are as follows:

	April 3,		December 31,
(MILLIONS OF DOLLARS)	2016		2015
Finished goods	$	765	$	758
Work-in-process	482		384
Raw materials and supplies	214		325
Inventories	$	1,461	$	1,467

10. Goodwill and Other Intangible Assets

A. Goodwill

The components of, and changes in, the carrying amount of goodwill are as follows:

(MILLIONS OF DOLLARS)	U.S.		International			Total
Balance, December 31, 2015	$	665	$	790		$	1,455
Additions / Adjustments(a)	—		(2		)	(2		)
Other(b)	—		6			6
Balance, April 3, 2016	$	665	$	794		$	1,459

^(a) Primarily includes a $12 million purchase price allocation associated with the acquisition of a livestock business in South America, offset by a $13 million reduction in the acquisition date fair value of goodwill associated with the acquisition of Abbott. See Note 4A. Acquisitions and Divestitures: Acquisitions.

^(b) Includes adjustments for foreign currency translation.

The gross goodwill balance was $1,995 million and $1,991 million as of April 3, 2016, and December 31, 2015, respectively. Accumulated goodwill impairment losses (generated entirely in fiscal 2002) were $536 million as of April 3, 2016, and December 31, 2015.

14 |

B. Other Intangible Assets

The components of identifiable intangible assets are as follows:

	As of April 3, 2016							As of December 31, 2015
						Identifiable							Identifiable
	Gross					Intangible Assets		Gross					Intangible Assets
	Carrying		Accumulated			Less Accumulated		Carrying		Accumulated			Less Accumulated
(MILLIONS OF DOLLARS)	Amount		Amortization			Amortization		Amount		Amortization			Amortization
Finite-lived intangible assets:
Developed technology rights(a)	$	1,038	$	(291	)	$	747	$	1,010	$	(274	)	$	736
Brands	212		(124		)	88		212		(121		)	91
Trademarks and trade names	64		(44		)	20		63		(44		)	19
Other(a)	227		(121		)	106		214		(118		)	96
Total finite-lived intangible assets	1,541		(580		)	961		1,499		(557		)	942
Indefinite-lived intangible assets:
Brands	36		—			36		36		—			36
Trademarks and trade names	67		—			67		66		—			66
In-process research and development	138		—			138		138		—			138
Product rights	8		—			8		8		—			8
Total indefinite-lived intangible assets	249		—			249		248		—			248
Identifiable intangible assets	$	1,790	$	(580	)	$	1,210	$	1,747	$	(557	)	$	1,190

^(a)  Includes the acquisition of intangible assets associated with the purchase of a livestock business in South America in the first quarter of 2016, as well as an increase in the acquisition date fair value of intangible assets associated with the acquisition of Abbott. See Note 4A. Acquisitions and Divestitures: Acquisitions.

C. Amortization

Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $24 million and $15 million for the three months endedApril 3, 2016, and March 29, 2015, respectively.

11. Benefit Plans

Our employees ceased to participate in the Pfizer, Inc. U.S. qualified defined benefit plans and the U.S. retiree medical plan effective December 31, 2012, and liabilities associated with our employees under these plans were retained by Pfizer. Pfizer is continuing to credit certain employees' service with Zoetis generally through December 31, 2017 (or termination of employment from Zoetis, if earlier) for certain early retirement benefits with respect to Pfizer's U.S. defined benefit pension and retiree medical plans. Pension and postretirement benefit expense associated with the extended service for certain employees in the U.S. plans totaled approximately $2 million in each three month period endedApril 3, 2016, and March 29, 2015, respectively.

The following table provides the net periodic benefit cost associated with our international defined benefit pension plans:

	Three Months Ended
	April 3,			March 29,
(MILLIONS OF DOLLARS)	2016			2015
Service cost	$	2		$	2
Interest cost	1			1
Expected return on plan assets	(1		)	—
Net periodic benefit cost	$	2		$	3

Total company contributions to the international pension plans were $3 million and $2 million for the three months endedApril 3, 2016, and March 29, 2015, respectively. We expect to contribute a total of approximately $8 million to these plans in 2016.

12. Share-Based Payments

The company may grant a variety of share-based payments under the Zoetis 2013 Equity and Incentive Plan (the Equity Plan) to employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock unit awards (DSUs), performance-vesting restricted stock unit awards (PSUs) and other equity-based or cash-based awards.

15 |

The components of share-based compensation expense are as follows:

	Three Months Ended
	April 3,		March 29,
(MILLIONS OF DOLLARS)	2016		2015
Stock options / stock appreciation rights	$	2	$	6
RSUs / DSUs	6		4
PSUs(a)	1		—
Share-based compensation expense—total(b)	$	9	$	10

^(a) For the three months ended March 29, 2015, share-based compensation expense related to PSUs was $0.3 million.

^(b) For the three months endedApril 3, 2016, and March 29, 2015, amounts capitalized to inventory were insignificant.

During the three months endedApril 3, 2016, the company granted 877,608 stock options with a weighted-average exercise price of $41.83 per stock option and a weighted-average fair value of $11.19 per option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 1.56%; expected dividend yield of 0.90%; expected stock price volatility of 26.85%; and expected term of 6.5 years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

During the three months endedApril 3, 2016, the company granted 708,021 RSUs with a weighted-average grant date fair value of $41.83 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs vest after three years of continuous service from the grant date and the values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

During the three months endedApril 3, 2016, the company granted 198,445 PSUs with a weighted-average grant date fair value of $50.20 per PSU. PSUs are accounted for using a Monte Carlo simulation model. The units underlying the PSUs will be earned and vested over a three-year performance period, based upon the total shareholder return of the company in comparison to the total shareholder return of the companies comprising the S&P 500 index at the start of the performance period (Relative TSR). The weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of peer companies, which were 23.8% and 25.2%, respectively. Depending on the company’s Relative TSR performance at the end of the performance period, the recipient may earn between 0% and 200% of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

13. Stockholders' Equity

Zoetis is authorized to issue 6,000,000,000 shares of common stock and 1,000,000,000 shares of preferred stock.

In November 2014, the company's Board of Directors authorized a $500 million share repurchase program. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs. As of April 3, 2016, there was approximately $225 million remaining under this authorization.

Changes in common shares and treasury stock were as follows:

(MILLIONS)	Common Shares Issued(a)	Treasury Stock(a)
Balance, December 31, 2014	501.34	0.02
Share-based compensation(b)	0.11	0.02
Share repurchase program	—	1.05
Balance, March 29, 2015	501.46	1.09
Balance, December 31, 2015	501.81	4.41
Share-based compensation(b)	0.08	(0.73	)
Share repurchase program	—	1.79
Balance, April 3, 2016	501.89	5.48

^(a)    Shares may not add due to rounding.

^(b)  Includes the issuance of shares of common stock and, beginning in the first quarter of 2016, the reissuance of shares from treasury stock in connection with the vesting of employee share-based awards. Treasury stock also includes the reacquisition of shares associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information regarding share-based compensation, see Note 12. Share-Based Payments.

16 |

Changes, net of tax, in accumulated other comprehensive loss, excluding noncontrolling interest, are as follows:

				Currency Translation
	Derivatives			Adjustment			Benefit Plans			Accumulated Other
	Net Unrealized			Net Unrealized			Actuarial			Comprehensive
(MILLIONS OF DOLLARS)	Gains/(Losses)			Gains/(Losses)			Gains/(Losses)			Loss
Balance, December 31, 2015	$	(2	)	$	(604	)	$	(16	)	$	(622	)
Other comprehensive income (loss), net of tax	—			3			1			4
Balance, April 3, 2016	$	(2	)	$	(601	)	$	(15	)	$	(618	)

14. Earnings per Share

The following table presents the calculation of basic and diluted earnings per share:

	Three Months Ended
	April 3,		March 29,
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2016		2015
Numerator
Net income before allocation to noncontrolling interests	$	204	$	165
Less: net income attributable to noncontrolling interests	—		—
Net income attributable to Zoetis Inc.	$	204	$	165
Denominator
Weighted-average common shares outstanding	497.4		501.1
Common stock equivalents: stock options, RSUs, PSUs and DSUs	2.1		2.1
Weighted-average common and potential dilutive shares outstanding	499.5		503.2
Earnings per share attributable to Zoetis Inc. stockholders—basic	$	0.41	$	0.33
Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	0.41	$	0.33

There were approximately 1 million stock options outstanding for each of the three-month periods ended April 3, 2016, and March 29, 2015, under the company’s Equity Plan that were excluded from the computation of diluted earnings per share as the effect would have been anti-dilutive.

15. Commitments and Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 7. Income Taxes.

A. Legal Proceedings

Our non-tax contingencies include, among others, the following:

• Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.

• Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.

• Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.

• Government investigations, which can involve regulation by national, state and local government agencies in the United States and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be

17 |

incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.

The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.

PregSure^®

We have received in total approximately 255 claims in Europe and New Zealand seeking damages related to calves claimed to have died of Bovine Neonatal Pancytopenia (BNP) on farms where PregSure BVD, a vaccine against Bovine Virus Diarrhea (BVD), was used. BNP is a rare syndrome that first emerged in cattle in Europe in 2006. Studies of BNP suggest a potential association between the administration of PregSure and the development of BNP, although no causal connection has been established. The cause of BNP is not known.

In 2010, we voluntarily stopped sales of PregSure BVD in Europe, and recalled the product at wholesalers while investigations into possible causes of BNP continued. In 2011, after incidences of BNP were reported in New Zealand, we voluntarily withdrew the marketing authorization for PregSure throughout the world.

We have settled approximately 158 of these claims for amounts that are not material individually or in the aggregate. Investigations into possible causes of BNP continue and these settlements may not be representative of any future claims resolutions.

Ulianopolis, Brazil

In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL) and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.

The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.

At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area. On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature, and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. The prosecutor, however, denied the proposal and reiterated his request that each defendant agree to become a signatory to the Term of Reference, as originally proposed. On October 5, 2015, we informed the prosecutor of our decision not to sign the Term Reference and requested a face-to-face meeting to clarify the scope and methodology of the preliminary assessment, to understand the exact reasons for the rejection of our proposal to engage a technical consultant, and to discuss alternative scenarios. The prosecutor granted our request and the meeting was held on November 6, 2015, at which we provided clarifications and additional information. We are in the process of negotiating the terms of the cooperation agreement with the prosecutor, pursuant to which the limited study at the site will be conducted.

Lascadoil Contamination in Animal Feed

An investigation by the U.S. Food and Drug Administration (FDA) and the Michigan Department of Agriculture is ongoing to determine how lascadoil, oil for industrial use, made its way into the feed supply of certain turkey and hog feed mills in Michigan. The contaminated feed is believed to have caused the deaths of approximately 50,000 turkeys and the contamination (but not death) of at least 20,000 hogs in August 2014. While it remains an open question as to how the lascadoil made its way into the animal feed, the allegations are that lascadoil intended to be sold for reuse as biofuel was inadvertently sold to producers of soy oil, who in turn, unknowingly sold the contaminated soy oil to fat recycling vendors, who then sold the contaminated soy oil to feed mills for use in animal feed. Indeed, related to the FDA investigation, Shur-Green Farms LLC, a producer of soy oil, recalled certain batches of soy oil allegedly contaminated with lascadoil on October 13, 2014.

During the course of its investigation, the FDA identified the process used to manufacture Zoetis’ Avatec® (lasalocid sodium) and Bovatec® (lasalocid sodium) products as one possible source of the lascadoil, since lascadoil contains small amounts of lasalocid, the active ingredient

18 |

found in both products. Zoetis has historically sold any and all industrial lascadoil byproduct to an environmental company specializing in waste disposal. The environmental company is contractually obligated to incinerate the lascadoil or resell it for use in biofuel. Under the terms of the agreement, the environmental company is expressly prohibited from reselling the lascadoil to be used as a component in food. The FDA inspected the Zoetis site where Avatec and Bovatec are manufactured, and found no evidence that Zoetis was involved in the contamination of the animal feed.

On March 10, 2015, plaintiffs Restaurant Recycling, LLC (Restaurant Recycling) and Superior Feed Ingredients, LLC (Superior), both of whom are in the fat recycling business, filed a complaint in the Seventeenth Circuit Court for the State of Michigan against Shur-Green Farms alleging negligence and breach of warranty claims arising from their purchase of soy oil allegedly contaminated with lascadoil. Plaintiffs resold the allegedly contaminated soy oil to turkey feed mills for use in feed ingredient. Plaintiffs also named Zoetis as a defendant in the complaint alleging that Zoetis failed to properly manufacture its products and breached an implied warranty that the soy oil was fit for use at turkey and hog mills. Zoetis was served with the complaint on June 3, 2015, and we filed our answer, denying all allegations, on July 15, 2015. On August 10, 2015, several of the turkey feed mills filed a joint complaint against Restaurant Recycling, Superior, Shur-Green Farms and others, alleging claims for negligence, misrepresentation, and breach of warranty, arising out of their alleged purchase and use of the contaminated soy oil. The complaint raises only one count against Zoetis for negligence. We filed an answer to the complaint on November 2, 2015, denying the allegation. We believe we have strong arguments against all claims.

Other Matters

The European Commission published a decision on alleged competition law infringements by several human health pharmaceutical companies on June 19, 2013. One of the involved legal entities is Alpharma LLC (previously having the name Zoetis Products LLC). Alpharma LLC's involvement is solely related to its human health activities prior to Pfizer's acquisition of King/Alpharma. Zoetis paid a fine in the amount of Euro 11 million (approximately $14 million) and was reimbursed by Pfizer in accordance with the Global Separation Agreement between Pfizer and Zoetis, which provides that Pfizer is obligated to indemnify Zoetis for any liabilities arising out of claims not related to its animal health assets. We filed an appeal of the decision on September 6, 2013.

In July 2014, we reached a commercial settlement with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. We recorded a $13 million charge in Other (income)/deductions—net in the second quarter of 2014, and we do not expect any significant additional charges related to this issue. In the third quarter of 2014, we were notified of an insurance recovery of $1 million and have recorded this in Other (income)/deductions—net.

On March 30, 2015, we were served with a complaint filed in the U.S. District Court for the Eastern District of Pennsylvania by two additional customers in Mexico, alleging damages suffered as a result of the use of poultry vaccines obtained from the recalled lots discussed above. We have moved to dismiss the complaint in its entirety on grounds that the complaint fails to properly state a claim on which relief can be granted. On September 16, 2015, the Court granted the motion in part and denied it in part, dismissing all claims arising out of tort or fraud. As a result, the only claims remaining in the lawsuit are based in contract, namely breach of express warranty, breach of certain implied warranties, and unjust enrichment.

B. Guarantees and Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April 3, 2016, recorded amounts for the estimated fair value of these indemnifications were not significant.

16. Segment and Other Revenue Information

A. Segment Information

We manage our operations through two geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceuticals, for both livestock and companion animal customers.

Operating Segments

Our operating segments are the United States and International. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

• Other business activities includes our Client Supply Services (CSS) contract manufacturing results, as well as expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.

19 |

• Corporate, which is responsible for platform functions such as business technology, facilities, legal, finance, human resources, business development, and communications, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.

• Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition-related activities, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.

• Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with business technology and finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) procurement costs.

Segment Assets

We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $7.5 billion at April 3, 2016, and $7.9 billion at December 31, 2015.

Selected Statement of Income Information

	Earnings						Depreciation and Amortization(a)
	April 3,			March 29,			April 3,		March 29,
(MILLIONS OF DOLLARS)	2016			2015			2016		2015
Three months ended
U.S.
Revenue	$	582		$	521
Cost of Sales	131			125
Gross Profit	451			396
Gross Margin	77.5		%	76.0		%
Operating Expenses	92			81
Other (income)/deductions	—			—
U.S. Earnings	359			315			$	6	$	6
International
Revenue(b)	567			571
Cost of Sales	196			204
Gross Profit	371			367
Gross Margin	65.4		%	64.3		%
Operating Expenses	109			135
Other (income)/deductions	2			2
International Earnings	260			230			11		11
Total operating segments	619			545			17		17
Other business activities	(74		)	(68		)	6		7
Reconciling Items:
Corporate	(169		)	(131		)	10		9
Purchase accounting adjustments	(26		)	(13		)	22		13
Acquisition-related costs	(1		)	(1		)	—		—
Certain significant items(c)	13			(41		)	1		1
Other unallocated	(30		)	(61		)	1		1
Total Earnings(d)	$	332		$	230		$	57	$	48

20 |

^(a)  Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

^(b)  Revenue denominated in euros was $154 million and $135 million for the three months endedApril 3, 2016, and March 29, 2015, respectively.

^(c)  For the three months endedApril 3, 2016, Certain significant items primarily includes: (i) Zoetis stand-up costs of $12 million; (ii) a net gain related to the sale of certain manufacturing sites and products of $33 million related to our operational efficiency initiative, partially offset by restructuring charges of $2 million and consulting fees of $3 million related to our operational efficiency initiative; and (iii) charges related to the supply network strategy of $3 million.

For the three months endedMarch 29, 2015, Certain significant items primarilyincludes: (i) Zoetis stand-up costs of $23 million; (ii) consulting fees related to our operational efficiency initiative and supply network strategy of $15 million; and (iii) charges due to unusual investor-related activities of $3 million.

^(d)  Defined as income before provision for taxes on income.

B. Other Revenue Information

Revenue by Species

Species revenue are as follows:

	Three Months Ended
	April 3,		March 29,
(MILLIONS OF DOLLARS)	2016		2015
Livestock:
Cattle	$	377	$	397
Swine	146		170
Poultry	122		129
Fish	17		—
Other	21		19
	683		715
Companion Animal:
Horses	39		40
Dogs and Cats	427		337
	466		377
Contract Manufacturing	13		10
Total revenue	$	1,162	$	1,102

Revenue by Major Product Category

Revenue by major product category are as follows:

	Three Months Ended
	April 3,		March 29,
(MILLIONS OF DOLLARS)	2016		2015
Anti-infectives	$	291	$	312
Vaccines	301		271
Parasiticides	145		153
Medicated feed additives	138		121
Other pharmaceuticals	221		187
Other non-pharmaceuticals	53		48
Contract manufacturing	13		10
Total revenue	$	1,162	$	1,102

17. Subsequent Events

On April 29, 2016, we completed the sale to Yung Shin Pharmaceutical Industrial Co., Ltd., of our 55 percent ownership share of our Taiwan joint venture including our manufacturing site in Hsinchu, Taiwan. See Note 4B. Acquisitions and Divestitures: Divestitures for additional information regarding the terms of the sale. The assets and liabilities related to the joint venture, including the manufacturing site, were included within held for sale classification as of April 3, 2016. This site exit represents one of the ten sites we plan to exit as part of our operational efficiency program. We received approximately $13 million in cash consideration, subject to working capital adjustments.

21 |

Review Report of Independent Registered Public Accounting Firm

The Shareholders and Board of Directors

Zoetis Inc.:

We have reviewed the accompanying condensed consolidated balance sheet of Zoetis Inc. and subsidiaries (the Company) as of April 3, 2016, and the related condensed consolidated statements of income, comprehensive income, equity and cash flows for the three-month periods ended April 3, 2016, and March 29, 2015. These condensed consolidated financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements as of